Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion
The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources. The post Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion appeared first…
The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources. The post Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion appeared first…
This is a summary of the story. Read the full article at GEN — Genetic Engineering & Biotechnology News ↗